Groningen

• CD8 PET imaging study before and after CAR T-cell therapy Ended
  2025-520560-18-00 10 2026-05-22 Large B-cell lymphoma
• PD-L1 PET imaging during CAR T-cell therapy Ended
  2024-518422-32-01 9 2026-05-20 (Diffuse) Large B-cell Lymphoma
• A Study to Track How the Healthy Male Participants Handles the New Oral Drug RO7795081 for Weight Management and Diabetes Ended
  2025-524210-28-00 3 2026-02-17 Not Applicable
• A study in healthy men to test how BI 1584862 is processed in the body Ended
  2025-522311-41-00 3 2026-01-22 Healthy volunteer trial
• A study investigating the effect of curcumin on the absorption and elimination of IMU 838, a new compound that may potentially be used in th … Ended
  2025-523791-24-00 3 2026-01-08 Multiple sclerosis
• A study to compare how the body absorbs different formulations of a new medicine, and how food affects drug absorption, in healthy participa … Ended
  2025-523430-14-00 3 2025-12-24 Psoriasis
• A study investigating the safety of RO7795074, a new compound that may potentially be used in the treatment of type 1 diabetes, and the effe … Ended
  2025-521921-34-00 3 2025-12-19 Overweight or Obese (otherwise healthy)
• A study in healthy men and women to test how BI 3000202 is taken up and processed by the body Ended
  2023-510345-21-00 3 2025-12-16 Healthy volunteer trial
• A Study Investigating the Safety and Absorption of Different Administration forms of RO7795074, a New Compound that may Potentially be Used … Ended
  2025-521888-13-00 3 2025-12-02 Overweight or Obese (otherwise healthy)
• A trial to evaluate the absolute bioavailability of cenerimod in healthy male participants Ended
  2025-522320-27-00 3 2025-11-17 Not applicable - healthy volunteer trial
• A Phase 1, Multi-Cohort, Open-Label, Randomized Pilot Study to Evaluate the Effect of Food and a Proton-Pump Inhibitor (esomeprazole) on the … Ended
  2025-523370-16-00 3 2025-11-17 Parkinsonian syndromes
• A study investigating the safety, absorption, and elimination of RO7795081, a new compound that may potentially be used in the treatment of … Ended
  2025-522766-78-00 3 2025-11-10 Not Applicable
• Phase 1 Study to Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Men Participants Ended
  2025-521402-18-00 3 2025-10-24 Desmoid tumor
• A study comparing different RO7269162 capsules and investigating the effect of food on the uptake, breakdown, and elimination of RO7269162 i … Ended
  2025-520616-33-00 3 2025-09-02 Not Applicable
• A Phase 1, Single-Center, Open-Label, Fixed-Sequence, 2-Part Study to Assess the Pharmacokinetics of IMU-838 Administered Alone and in Combi … Ended
  2025-521754-41-00 3 2025-08-15 Multiple sclerosis
• A Phase 1 study to evaluate the metabolism of [14C]PF-07104091 in healthy adult male participants Ended
  2024-518696-65-00 3 2025-08-12 (HR) -positive human epidermal growth factor receptor 2 (HER2) -negati
• A study to learn how the study medicine called [14C]PF-07054894 is processed by the body. Ended
  2024-519882-23-00 3 2025-06-13 Inflammatory bowel disease.
• Phase 1 study on SAR443122 bioavailability and food effect in healthy adults Ended
  2025-521073-13-00 2 2025-06-11 Colitis ulcerative
• A study to assess the safety of ARGX-121 in Healthy Adult Participants Ended
  2025-521524-30-00 1 2025-06-05 Healthy volunteers
• A study investigating the safety, absorption, and elimination of NNC0705-0001, a new compound that could potentially be used in the treatmen … Ended
  2024-519478-38-00 1 2025-06-03 Cardiometabolic diseases with an inflammatory component
• A Study to Understand What the Body Does to the Study Medicine Called PF-07976016 When Taken by Healthy Adults Ended
  2024-518535-11-00 3 2025-05-30 Obesity
• WOMEN&More: Efficacy, safety, and acceptability of mifepristone 50 mg once-weekly as a contraceptive Ended
  2022-502694-41-00 5 2025-04-14 Contraception
• A Study to Learn How a Tablet Compared with an IV Infusion of the Study Medicine Called Vepdegestrant is Taken up into the Blood in Healthy … Ended
  2024-518134-92-00 3 2025-04-02 ER+/HER2- breast cancer
• Intralesional Cemiplimab for Adult Patients with Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma Ended
  2024-511440-76-00 1 2025-03-20 Cutaneous Squamous Cell Carcinoma

Showing 481–504 of 679 trials